TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Status:
RECRUITING
Trial end date:
2030-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas